Crigler-Najjar type 1 disease (CN-1) is a genetic disorder characterized by high levels of unconjugated bilirubin due to the absence of hepatic UDPglucuronosyltransferase (UGT1) activity. Here we show that in vivo neonatal hepatocyte transduction with a lentiviral vector expressing the defective enzyme resulted in long-term correction in Gunn rats, a model of CN-1. Lentiviral vectors harboring the human UGT1 cDNA (approved symbol UGT1A1) under the control of a liver-specific transthyretin promoter were produced. Two-day-old Gunn rats were injected with 50 Ml of vector. Bilirubinemia was monitored at 6 weeks and monthly thereafter. At 6 weeks, bilirubinemia was completely normalized in treated animals, whereas it remained around 100 MM in control rats. The level of correction remained stable for up to 42 weeks. Large amounts of bilirubin conjugates were present in the bile of corrected animals. PCR and Western blots confirmed the presence and expression of UGT1 in liver. The estimated proportion of transduced hepatocytes was 40% and transduced cells were not detected in extrahepatic tissues except bone marrow in some animals. This work represents the first demonstration of a complete and permanent correction of hyperbilirubinemia in Gunn rats using lentiviral vectors.
INTRODUCTION
Crigler-Najjar type I disease (CN-1) is a rare recessive inherited disorder of metabolism caused by complete inactivation of the enzyme bilirubin glucuronosyltransferase (UGT1; EC 2.4.1.17). Bilirubin is a by-product in the degradation pathway of hemoglobin and is conjugated to glucuronic acid in liver microsomes by UGT1 to form a water-soluble derivative that is eliminated in the bile. In CN-1 patients, unconjugated bilirubin chronically accumulates to very high levels in most tissues, resulting in severe jaundice as well as a life-threatening neurotoxic injury referred to as kernicterus. Bilirubin may be degraded by exposure to UV light and prolonged daily sessions of UV phototherapy are required in CN-1 patients. The only curative alternative to phototherapy is liver transplantation. CN-1 disease is an attractive candidate disease for gene therapy for a number of reasons. (i) CN-1 results from a single genetic defect that accounts for the whole clinical spectrum of symptoms, (ii) the histology of the liver parenchyma remains strictly normal throughout the course of the disease, (iii) the liver is a unique organ harboring a fenestrated endothelium that makes it easily accessible to many types of gene transfer vectors delivered to the blood stream, and (iv) the existence of a mutant jaundiced rat first identified by Gunn [1] and which replicates the human CN-1 disease has facilitated in vivo evaluation of gene therapy strategies aimed at correcting bilirubin conjugation deficiencies. For unknown reasons, bilirubinemia in Gunn rats rarely exceeds 200 AM and the animals do not develop kernicterus. Therefore, although cerebellar lesions as well as deafness may be present, there is no specific clinical phenotype and the hallmark of the disease is restricted to high serum bilirubin.
During the past decade a wide array of gene transfer vectors were tested for their capacity to correct hyperbilirubinemia in Gunn rats. However, two major hurdles emerged that hampered the clinical development of gene therapy for CN-1 patients. On the one hand, absence of complete correction of hyperbilirubinemia was observed with some gene transfer vectors. For example, murine oncoretroviral vectors administered to the regenerating liver following partial hepatectomy resulted in sustained correction, albeit partial and limited to a 33% decrease of serum bilirubin level [2] . Similarly, UGT1 gene (approved symbol UGT1A1) transfer using multiple intraportal injections of a replication-defective SV40 vector resulted in partial (70% decrease) and sustained amelioration of bilirubinemia in Gunn rats [3] . On the other hand, an immune response directed to the therapeutic protein or to viral vector proteins precluded the long-term correction of Gunn rats even when complete reversion of the disease phenotype was achieved. Initial studies using first-generation adenoviral vectors demonstrated complete normalization of serum bilirubin levels that disappeared after 3 weeks [4] . Cytotoxic T-cell-mediated rejection of transduced hepatocytes accounted for correction loss. Subsequently, immune modulation of the recipient animal to induce tolerance or to disable immune response, as well as modification of the vector backbone to express immunomodulatory molecules such as CTLA4Ig, was evaluated [5] [6] [7] [8] [9] . All these strategies improved the duration of correction but complete permanent correction of phenotype was not obtained in Gunn rats until recently. Indeed, Toietta et al. reported very recently the complete correction of Gunn rats after delivery of gutted adenoviral vectors in adult animals. The correction was sustained for the life of the animals without significant toxicity [10] .
Another promising approach to circumventing immune response is to take advantage of the immaturity of the immune system during fetal life. Recently it was shown that UGT1 lentiviral vectors injected during pregnancy in Gunn rats resulted in partial correction of bilirubinemia that was sustained for at least 1 year [11] . Along the same line, it was shown that delivery of an oncoretrovirus ferrying the human factor IX cDNA to newborn mice resulted in prolonged expression of the protein with no induction of an immune response [12] . Previous attempts to correct Gunn rats by neonatal injection of adenoviral vectors failed, presumably because of the absence of integration of the therapeutic gene using this type of vector and subsequent progressive loss of the transgene in the growing liver [13] .
Based on these premises, the goal of our study was to evaluate whether administration to newborn Gunn rats of a high titer UGT1-expressing lentiviral vector, known to integrate into the genome of infected cells, could result in the complete and permanent phenotypic correction without immune elimination of the corrected hepatocytes.
RESULTS

Correction of Bilirubinemia in Treated Animals
We injected 2-day-old homozygous Gunn j/j animals of both genders and from different litters via the temporal vein with a lentiviral vector carrying the human UGT1 cDNA under the control of a liver-specific murine transthyretin (mTTR) promoter (mTTR-UGT1 vector, group 1, n = 7). Homozygous affected animals can easily be distinguished from their heterozygous littermates because jaundice is clearly visible at birth. Moreover, we genotyped the animals used in the experiments by PCR as previously described [14] . Primers located apart from the point mutation at position 1239 of the rat UGT1 cDNA amplified a 379-bp DNA fragment that was never cleaved by BstNI in homozygous Gunn j/j animals. In contrast, two fragments (230 and 149 bp) were present in heterozygous as well as in control wild-type animals ( Fig. 1) . Control animals were uninjected animals (group 2, n = 10) as well as animals receiving a lentiviral vector encoding GFP under the control of the mTTR promoter (mTTR-GFP, group 3, n = 6). At 6 weeks of age, we measured serum bilirubin levels in all animals. At that FIG. 1. PCR genotyping of experimental animals. The rat UGT1 cDNA was amplified by PCR as described under Material and Methods and the resulting fragment was digested by BstNI. Cleavage occurred only in the wild-type allele. Shown are wild-type DNA (+/+), homozygous jaundiced DNA (j/j), and heterozygous DNA (j/+). Each lane number corresponds to DNA from one experimental rat, all of which were j/j homozygous.
FIG. 2.
Time-course analysis of serum bilirubin levels in treated and control homozygous j/j Gunn rats. Each value plotted represents the mean F SD. time the mean bilirubinemia was similar in both control groups (69.2 F 14.6 AM in uninjected rats vs 78.33 F 3.2 AM in GFP-injected, P = 0.16 using Student's t test), showing that injection of nontherapeutic lentiviral vectors did not affect hyperbilirubinemia. In contrast, in animals injected with mTTR-UGT1, bilirubinemia (mean 3.43 F 5.56 AM) was in the same range as in wild-type or heterozygous animals (i.e., b10 AM). This indicates that the phenotypic correction was rapid and complete, as also illustrated by change in the serum color: from yellow for untreated jaundiced Gunn rats to transparent for treated rats. We monitored serum bilirubin levels further monthly. As shown in Fig. 2 , phenotypic correction was stable with time and bilirubinemia remained in the normal range for up to 42 weeks (monitoring of the animals is still ongoing). In contrast, bilirubinemia increased with time to around 120 AM in the control animals.
Excretion of Bilirubin Glucuronides in Bile
To document restoration of hepatic bilirubin glucuronidation in treated animals, we harvested bile from UGT1-injected animals at 22 weeks of age and analyzed it by HPLC to demonstrate the presence of bilirubin glucuronide derivatives. The HPLC profile of group 1 rats was similar to the typical HPLC profile of wild-type Wistar animals and the peaks corresponding to bilirubin monoglucuronide and diglucuronide were clearly visible (Fig. 3) . In contrast, there was no secretion of bilirubin glucuronides in the bile of uninjected control rats (Fig. 3) or of control rats injected with mTTR-GFP (not shown). A precise quantification of the proportion of bilirubin glucuronides showed that the two glucuronides accounted for more than 99% of bile pigments in three animals of the treated group (Table 1) . This was almost identical to Wistar rats in which unconjugated bilirubin accounted for about 1-5% of the bile pigments ( Table 1) . The presence of unconjugated bilirubin in Wistar rats may result from the presence of photoderivatives of bilirubin produced by exposure to light at the time of harvest. Interestingly, as previously reported in other studies, in which bilirubinemia was nearly corrected by delivery of human UGT1 transgene, we observed that in treated animals bilirubin diglucuronides were predominant over bilirubin monoglucuronides [11, 15] . This is in contrast to control wild-type animals, which had a reverse proportion of both derivatives. However, it is consistent with efficient gene transfer since it has been previously demonstrated that the proportion of bilirubin diglucuronides paralleled UGT1 enzyme activity in rats [16] .
Liver Biopsy Analysis
We harvested surgical biopsies from the liver of a panel of group 1 animals at week 22. The presence as well as the expression of the transgene was revealed by PCR and immunoblot. Semiquantitative PCR revealed the presence of the human UGT1-specific 504-bp fragment in treated animals (Fig. 4) . This band was absent in control animals. We constructed a standard curve by diluting human genomic DNA in rat genomic DNA to compare the PCR signal intensity from treated animals. The maximal signal intensity was obtained in rat 1-F. It is worth noting that this animal had the highest proportion of bilirubin glucuronides in bile (Table 1) . We also analyzed DNA samples using real-time PCR for the human UGT1 sequence of the mTTR-UGT1 vector and normalized it to the phosphoenol pyruvate kinase (PEPCK) sequence of the rat genome. We used human genomic DNA mixed with rat genomic DNA to create standards for vector copies per rat diploid genome. The average for the treated animals was 0.5 F 0.26 copy of vector per haploid genome in the liver. Immunoblot detection of UGT1 protein in liver microsomes of treated animals revealed the same 52-kDa immunoreactive band as in control human liver, which corresponds to human UGT1 (Fig. 5) . This band was absent in uninjected control animals.
To evaluate the proportion of transduced hepatocytes after neonatal in vivo delivery of lentiviral vectors, we performed immunohistochemical detection of GFP in liver from four control animals injected with mTTR-GFP vector (Fig. 6) . Indeed, in accordance with a previous study, we could not detect UGT1A1 in liver sections by immunohistochemistry using the WP1 anti-human UGT1 antibody [11] . Because similar amounts of viral 4 . Semiquantitative PCR analysis of liver DNA after UGT1 gene transfer in homozygous j/ j rats. High-molecular-weight DNA was extracted from liver biopsies and the presence of the UGT1 gene was detected by semiquantitative PCR. As a control, a 202-bp fragment from the rat PEPCK gene promoter was amplified. A standard curve was constructed by mixing the indicated proportions of human genomic DNA with rat genomic DNA (top). PCR analysis was performed for three experimental animals (1-E, 1-F, and 1-G) on undiluted DNA (500 ng) or DNA diluted 10-(50 ng) and 100-fold (5 ng). M.W., molecular weight markers.
particles were infused in UGT1-treated and GFP control animals, the proportion of GFP-transduced hepatocytes should reflect the proportion of lentivirally transduced hepatocytes in UGT1-injected animals [11] . Lentivirally transduced hepatocytes were distributed throughout the liver parenchyma. The mean number of transduced hepatocytes was 36.15 F 29% (minimum 10.3%, maximum 70%, data not shown) and was in agreement with the PCR experiments. GFP-positive cells were not detected in uninjected rats. We did not detect nonparenchymal cells stained by immunohistochemistry using anti-GFP antibodies, which is in accordance with the liver specificity of the mTTR promoter.
Tissue Distribution of the Transgene
Because delivery of viral vectors to the bloodstream should result in transduction of multiple organs, we performed semiquantitative PCR detection of human UGT1 cDNA in various organs of two treated animals. We observed a positive signal in the liver of both animals. A faint band was also present in the bone marrow DNA in one animal. All other tested organs were negative, indicating that transduction of organs with a continuous endothelium either was absent or occurred at a low level (Fig. 7) .
DISCUSSION
CN-1 disease represents a paradigm for the gene therapy of inherited liver disorders for a number of reasons. It is a monogenic disease that does not injure the liver parenchyma. Because the toxic product that accumulates during the course of the disease, unconjugated bilirubin, is lipophilic, it can easily be taken up by a small proportion of corrected cells and there is no need to transduce the whole liver to get a therapeutic effect. The disease is detected early after birth and CN-1 patients are amenable to various strategies of gene delivery as well as to cell therapy [17, 18] . Finally the existence of an animal model mimicking the human disease has made it possible to devise preclinical approaches of gene therapy. A wide array of gene transfer vectors harboring the human UGT1 cDNA has been designed and their efficacy has been evaluated in Gunn rats. All these studies conclusively demonstrated the validity of gene replacement therapy for improving the hallmarks of the disease in this model although no complete and permanent correction was achieved until recently. As an example, first-generation adenoviral vector-mediated gene delivery to the liver resulted in a transient complete correction that was rapidly abrogated by a strong immune rejection of transduced cells [4] . Various strategies to circumvent the immune response triggered by this highly immunogenic vector type were designed and tested in Gunn rats [6, 7, 9 ]. An encouraging study reported that adenovirus-mediated gene transfer to newborn animals decreased rejection of transduced cells [13] . However, hyperbilirubinemia eventually resumed in all   FIG. 5 . Western blot analysis of rat liver after UGT1 gene transfer. Microsomes were prepared from liver biopsies of three animals (1-E, 1-F, 1-G) 22 weeks after gene transfer. After immunoblotting, the presence of UGT1 protein was detected in all treated animals but was absent in uninjected control (Ctrl). Human liver, control human microsomes.
FIG. 6.
Immunohistochemical detection of transduced hepatocytes in GFPinjected animals. The presence of GFP-positive hepatocytes was detected by immunohistochemistry as described under Material and Methods. This picture was obtained in an experimental animal with 40% GFP-positive hepatocytes. Hematoxylin counterstained. Original magnification Â220.
FIG. 7.
Determination of vector dissemination by PCR. High-molecular-weight genomic DNA was prepared from various organs of two mTTR-UGT1-injected j/j Gunn rat at 3 months after gene delivery. The presence of the UGT1 cDNA was detected by PCR. As a control, a 202-bp fragment from the rat PEPCK gene promoter was amplified. M.W., molecular weight markers.
cases after several weeks. Very recently, Toietta et al. reported the complete and permanent correction of Gunn rats after a single injection of gutted adenoviral vectors in adult animals [10] . However, the clinical application of this approach is still questionable. The absence of toxicity of adenoviral vectors in rat does not preclude potential toxicity in human. This issue is of particular importance since a previous clinical trial of gene therapy for OTC deficiency using adenoviral vectors resulted in the death of a young patient attributed to innate immunity immediately after injection [19] . The dose of vector injected into the patient (6 Â 10 11 viral particles/kg) was lower than the dose required to treat the Gunn rats (3 Â 10 12 particles/kg). Retroviral vectors govern integration of the transgene into the genome of target cells. Therefore, the correction level achieved after infection is constant over time whatever the number of subsequent divisions of the corrected cell. This is particularly important when gene therapy is aimed at treating young children. Such sustained correction was reported in studies in which lentiviral vectors were delivered in utero as well as when oncoretroviral vectors were delivered after partial hepatectomy in adult Gunn rats [2, 11] . In both studies, correction was sustained for prolonged periods of time (up to 1 year). However, since oncoretroviral vectors are less efficient than adenoviral vectors at transducing hepatocytes, a complete correction was never achieved. In our present study we demonstrated that when high-titer integrative vectors are delivered to newborn animals, a sufficient amount of hepatocytes is targeted and a complete correction is achieved. Moreover, this complete correction is sustained even during growth of treated animals.
We previously reported that when high-titer retroviral vectors were delivered to the liver of adult rats following partial hepatectomy, the decrease of serum bilirubin level was blunted by an immune response that eliminated transduced cells in less than 4 weeks [20] . It has recently been reported that in vivo delivery of recombinant retroviruses to newborn mice could induce tolerance to nonself proteins [12] . Such a mechanism may account for the absence of immune response against UGT1 in our study. In one animal PCR analysis revealed the presence of the transgene in bone marrow cells and therefore transduction of bone marrow stem cells is likely as it has been previously reported after neonatal delivery of oncoretroviruses [21] . However, it must be stressed that the development kinetics of the immune system may differ in humans and in rodents. Therefore, prenatal delivery of the vectors (e.g., in utero) may be required to achieve tolerance in humans.
Tolerance may also result from the restricted expression of UGT1 in hepatocytes and not in professional antigen-presenting cells, avoiding the development of transgene-specific cellular and humoral immune responses [22] . More generally, liver-specific promoters would be preferable to target transgene expression in hepatocytes and could be superior to ubiquitous promoters with regard to level and very long term transgene expression in liver.
Hyperbilirubinemia is easily detected early after birth. Although the genetic diagnosis for CN-1 disease may not be established in the very first days of life, patients amenable to gene therapy are not older than 2 to 3 months. Our study warrants that strong consideration be given to a clinical trial for CN-1 based on the in vivo delivery of lentiviral vectors harboring the human UGT1 cDNA under control of a liver-specific promoter.
MATERIAL AND METHODS
Description and production of lentiviral vectors. High-titer lentiviral vector stocks were generated as previously described by calcium phosphate-mediated transient transfection of three plasmids: the transfer vector plasmid, the packaging plasmid pCMVDR8.91, and the VSVG envelope protein-coding plasmid pMD.G [23] . These self-inactivating transfer vectors harbored the human UGT1 cDNA under control of a promoter that specifically directs transcription to the liver, the murine transthyretin promoter fused to a synthetic hepatocyte-specific enhancer [24, 25] . They also harbored the cis-acting cPPT/CTS from HIV-1, which facilitates the nuclear translocation of preintegrative vector complexes [26, 27] and the posttranscriptional regulatory element from the woodchuck hepatitis virus, which increases transgene expression [28] and was inserted downstream of the transgene. Control viruses containing the GFP gene under control of the same promoter were also produced and used as controls. The titers of the viral preparations were determined on HeLa cells by real-time quantitative PCR using primers and probe specific for 5V-untranslated lentiviral vectors: GAG-F, GGAGCTAGAACGATTCGCAGTTA; GAG-R, GGTTGTA-GCTGTCCCAGTATTTGTC; and GAG-P, 5V-(FAM)-ACAGCCTTCTGATG-TTTCTAACAGGCCAGG-(Eclipse Dark Quencher)-3V. For normalization of the amounts of genomic DNA, primers and probe specific for the aactin gene were used: HB2-F, TCCGTGTGGATCGGCGGCTCCA; HB2-R, CTGCTTGCTGATCCACATCTG; and 5V-(Yakima yellow)-CCTGGCCTC-GCTGTCCACCTTCCA-(Eclipse Dark Quencher)-3V. Reactions were performed and analyzed using an ABI Prism 7700 sequence detection system (RE-Applied Biosystems). The titer routinely reached 10 10 HeLa transducing units/ml.
Animal experiments. All animals were housed at the animal facilities of Nantes University Medical school and received human care according to the guidelines of the French Ministère de l'Agriculture. Homozygous Gunn j/j rats of both genders were used in this study. They were obtained from our breeding colony by mating homozygous Gunn j/j males with heterozygous j/o females.
At birth, homozygous icteric pups were easily distinguished from heterozygous littermates by simple examination of the yellow coloration of the tegument. Moreover, a genetic confirmation of homozygosity was achieved in adulthood by the enzymatic restriction of PCR fragments encompassing the point mutation in the common exon of the UGT1 gene family [29, 30] . To this end high-molecular-weight DNA was extracted from primary blood mononuclear cells and a portion was subjected to amplification by PCR using primers (sense, 5V-GGGATTCTCAGAATCTA-GACATT-3V; antisense, 5V-GTGTGTGGTATAAATGCTGTAGG-3V). The samples were submitted to 32 cycles of amplification (948C for 30 s for denaturation, 558C for 30 s for annealing, and 728C for 1 min for elongation). The amplicon that was 379 bp in size was analyzed with or without digestion with the restriction enzyme BstNI [14] . The amplification product of homozygous j/j Gunn rat DNA lacks the restriction site for BstNI and, therefore, yields a single band (379 bp). The restriction pattern of wild-type controls yields two bands (230 and 149 bp). In heterozygous j/ o littermates both patterns are visible. At day 2 of life, lentiviral vectors (5 Â 10 8 infectious particles in 50 Al PBS containing 8 Ag/ml Polybrene) were injected via the temporal vein.
Bilirubin assays. Six weeks after gene delivery and monthly thereafter, blood samples were drawn from the retro-orbital sinus for serum analysis. Serum total bilirubin levels were measured spectrophotometrically on a Hitachi 717 apparatus using the Bil-T kit (Boehringer Mannheim France, Meylan, France). Bile was harvested by laparotomy and cannulation of the main bile duct using a fine polyethylene catheter (PE 10). The presence of monoglucuronide and diglucuronide bilirubin conjugates in the bile was assessed using alkaline methanolysis as previously described [31] .
Western blot analysis. Total microsomes (100,000g supernatant) were isolated from liver biopsies by ultracentrifugation. Protein contents were determined using the Bio-Rad protein assay kit. For immunoblot analysis, proteins (40 Ag/lane) were resolved by electrophoresis on a 10% polyacrylamide gel. After electrophoretic transfer onto nitrocellulose membranes, immunoblots were incubated sequentially with 5% low-fat milk blocking solution and the human WP1 primary antibody diluted 1:5000. The WP1 antibody interacts with the common carboxy-terminal domains of human UGT1 isoforms [32] . The secondary antibody was biotinylated conjugated anti-mouse Ig FVab fragment that was detected by using the ECL Western blotting detection system (Amersham Biosciences). Human hepatic microsomes were used as positive control.
PCR analysis. High-molecular-weight DNA (500 ng) was subjected to amplification by PCR using primers (5V-TCTGCTATGCTTTTGTCTGG-3V and 5V-GGATAGTGGATTTTGGTGAA-3V) specific for human UGT1. Semiquantitative PCR amplification was performed by denaturation for 5 min at 948C, followed by 28 cycles of amplification (948C for 20 s, 608C for 30 s, 728C for 40 s), and a final extension for 10 min at 728C. The resulting amplified fragment was 504 bp. We carried out a positive control by amplification of a 202-bp fragment of the rat PEPCK gene promoter using the two primers 5V-GTCATATTTCTTCAGCTTGCG-3V and 5V-ATAATGGT-CTGGACTTCTCTG-3V. Serial dilutions of human genomic DNA in rat genomic DNA were used as a standard curve. Amplified products were separated by gel electrophoresis on 2% agarose gel and DNA bands were revealed by ethidium bromide staining.
Real-time quantitative PCR was performed using Sybr Green I dye (Perkin-Elmer Biosystems) with an ABI Prism 7700 sequence detection system. The values were normalized for the amount of DNA using amplification of a PEPCK gene as an internal standard. The sequence of the forward primer was 5V-GTGATGATGCCCTTGTTTGGT-3V and that of the reverse primer was 5V-AAACTCCACCCAGAACACGG-3V. A 96-well optical tray and caps were used with a final reaction mixture containing 50 ng of DNA, 7.5 pmol (each) of the forward and reverse primers, and Sybr Green PCR Master Mix (PE Biosystems). Reaction conditions were 508C for 2 min, 958C for 10 min, followed by 40 cycles at 958C for 15 s and 608C for 1 min. The amplicon generated was 228 bp. A standard scale was constructed using human genomic DNA diluted in various proportions with rat genomic DNA. Results are expressed as C t values for each sample.
Immunohistochemistry. The presence of GFP-positive hepatocytes was assessed by immunohistochemistry on formalin-fixed/paraffin-embedded sections (5 Am). Sections were deparaffinized and endogenous peroxidase activity was inhibited by incubation for 30 min in a 3% H 2 O 2 solution in PBS. Monoclonal primary mouse anti-GFP antibody diluted 1:100 in PBS containing BSA (2% w/v) and Tween 20 (0.1% v/v) was applied for 2 h at room temperature. GFP-positive cells were revealed with biotinylated goat anti-mouse immunoglobulin and streptavidin-peroxidase using diaminobenzidine as a chromogenic substrate. Slides were counterstained with hematoxylin and the GFP-positive cell index was calculated as the percentage of positively stained cells in 10 fields at 40Â magnification (i.e., at least 3000 cells).
Statistical analysis. Statistical analysis was performed using the Student t test. A P value of less than 0.05 was considered to be statistically significant.
